Pivotal Study in VAP Suspected or Confirmed to be Due to Pseudomonas Aeruginosa
Status:
Terminated
Trial end date:
2019-07-17
Target enrollment:
Participant gender:
Summary
This is a phase 3, multicenter, open-label, randomized active-controlled, parallel group to
investigate the efficacy, safety and tolerability, and pharmacokinetics of intravenous
murepavadin combined with of one anti-pseudononas antibiotic with that of two
anti-pseudomonas antibiotics in the treatment of ventilator-associated bacterial pneumonia
(VABP) in adult subjects.